Orforglipron vs Wegovy: Comparison Guide

Orforglipron vs Wegovy: Comparison Guide

The landscape of weight management is evolving, with new medications offering more options than ever before. Among these are powerful drugs known as GLP-1 receptor agonists. Wegovy (semaglutide) is a well-established option in this class. Orforglipron, sold as Foundayo, is a newer once-daily pill from Eli Lilly that the FDA approved in April 2026 and the UK's MHRA authorised in August 2026.

Understanding the similarities and differences between them can help you have a more informed conversation with your doctor. This guide offers a clear, evidence-aware comparison of orforglipron and Wegovy. Consult your healthcare provider before starting any medication.

Understanding the Medications: How Do They Work?

At their core, both orforglipron and Wegovy function in a similar way. They belong to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.

The Shared Mechanism: GLP-1 Receptor Agonists

GLP-1 is a natural hormone produced in your gut. When you eat, your body releases GLP-1, which sends signals to your brain that you are full. It also slows down how quickly your stomach empties and helps regulate blood sugar.

Both Wegovy and orforglipron mimic the effects of this natural hormone. By activating GLP-1 receptors in the body, they help:

• Reduce appetite and food cravings.
• Increase feelings of fullness (satiety), leading you to eat less.
• Slow the passage of food from the stomach into the intestines.

This shared mechanism is what makes them effective tools for chronic weight management when used alongside diet and exercise.

Key Differences: A Head-to-Head Look

While they work similarly, the most significant differences between orforglipron and Wegovy lie in their administration, molecular structure, and current availability.

Active Ingredient

• Wegovy: The active ingredient is semaglutide.
• Orforglipron: The active ingredient is orforglipron.

Administration: Injection vs. Pill

This is perhaps the most practical and important difference for many people.

• Wegovy is best known as a once-weekly subcutaneous injection, using a small, pre-filled pen to inject the medication just under the skin of the abdomen, thigh, or upper arm. In the US, Wegovy is also approved as a once-daily tablet (the Wegovy pill, approved in December 2025), which has strict rules about taking it on an empty stomach.

• Orforglipron (Foundayo) is a once-daily oral pill that the US label says can be taken with or without food. This makes it an option for people who prefer not to take an injectable medication.

Molecular Structure: Peptide vs. Non-peptide

The reason for the difference in administration comes down to science.

• Wegovy (semaglutide) is a peptide-based molecule. Peptides are essentially small proteins. Taken as a standard pill, most would be broken down in the stomach before they could be absorbed, which is why semaglutide is usually injected. Oral semaglutide tablets exist, but they use an absorption enhancer and must be taken on an empty stomach with only a little water.

• Orforglipron is a non-peptide "small molecule." It was specifically designed to be stable enough to withstand stomach acid and be absorbed effectively when taken orally. This innovation is what allows it to be formulated as a daily pill.

Current Availability

• Wegovy is approved for chronic weight management by regulatory agencies in many countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It is currently available by prescription.

• Orforglipron (Foundayo) was approved by the FDA on 1 April 2026 for weight management in adults with obesity, or overweight with at least one weight-related condition. The UK's MHRA authorised it on 10 August 2026 for weight management and for type 2 diabetes. As of October 2026 it is not approved in India; Lilly has said an India launch could come in 2027 if regulators approve it. Availability and coverage are changing quickly, so check with your prescriber or pharmacist.

Comparing Efficacy and Safety Profiles

Data from extensive clinical trials gives us insight into the potential effectiveness and side effects of both medications.

Weight Loss Results in Clinical Trials

Both medications have demonstrated significant weight loss in their respective clinical trials.

• Wegovy: In the landmark STEP 1 clinical trial, participants taking semaglutide 2.4 mg combined with lifestyle intervention lost an average of nearly 15% of their initial body weight over 68 weeks.

• Orforglipron: In a 36-week Phase 2 trial, average weight loss was up to about 14.7% at the highest doses. In the larger 72-week Phase 3 trial in adults without diabetes (ATTAIN-1), the US label reports an average loss of 11.1% of body weight on the highest dose (17.2 mg), compared with 2.1% on placebo. These results are somewhat lower than those seen with injectable semaglutide 2.4 mg, though the trials were not head-to-head.

It is important to remember that individual results can vary, and these medications are most effective as part of a comprehensive weight management plan that includes diet and physical activity.

Common Side Effects

Because they share the same mechanism of action, orforglipron and Wegovy also share a similar side effect profile. The most commonly reported side effects are gastrointestinal in nature and include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain

These side effects are typically mild to moderate and often decrease as the body adjusts to the medication. Doctors usually start patients on a low dose and gradually increase it over several weeks or months to help manage these effects.

Both medicines carry the same important warnings in their US labels, including a boxed warning about thyroid C-cell tumours (they should not be used if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2), and warnings about pancreatitis, gallbladder disease, kidney problems from dehydration, and low blood sugar when used with insulin or a sulfonylurea. With Foundayo, the label advises people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. Neither medicine should be used in pregnancy.

Seek urgent medical help if you have severe stomach pain that does not go away (with or without vomiting, sometimes spreading to your back), signs of an allergic reaction such as swelling of the face or throat or trouble breathing, or vomiting and diarrhoea that stop you keeping fluids down. Tell anyone doing surgery or sedation that you take a GLP-1 medicine.

Who Might Be a Candidate?

These medications are generally intended for adults with obesity (a BMI of 30 or greater) or who are overweight (a BMI of 27 or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

However, the final determination of whether a medication is appropriate is always made by a qualified healthcare professional. They will consider your complete health history, current health status, and other medications you may be taking.

Making an Informed Choice

Choosing a weight management strategy is a personal decision made in partnership with your healthcare team. When considering medications like Wegovy and orforglipron (Foundayo), the discussion will likely revolve around several key points:

• Administration: Your comfort level with a once-weekly injection versus a once-daily pill is a primary consideration.
• Availability: Wegovy is widely approved and available. Foundayo is approved in the US and UK but is newer and not yet available everywhere, including India (as of October 2026).
• Lifestyle: How a daily pill or a weekly injection fits into your routine.
• Personal Health Profile: Your unique medical history will guide your doctor's recommendation.

These medications represent a significant advancement in weight management, offering powerful tools to support health goals. The right path forward is one that is safe, sustainable, and tailored to you. Consult your healthcare provider before starting any medication.

Sources

• Wegovy (semaglutide) injection and tablets, Prescribing Information - FDA
• Foundayo (orforglipron) tablets, Prescribing Information - Eli Lilly
• UK first in Europe to authorise orforglipron for weight management and type 2 diabetes - GOV.UK
• Eli Lilly may launch oral obesity drug Foundayo in India in 2027 - Free Press Journal
• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial) - NEJM
• Daily Oral Orforglipron for Adults with Obesity (Phase 2 Trial) - NEJM
• GLP-1 agonists: What they are, how they work, and what they do - Cleveland Clinic
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) - ClinicalTrials.gov